There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
From the Research
Presentation of Transverse Myelitis (TM)
- Clinical presentation of TM typically includes some combination of motor weakness, sensory symptoms, and bowel and bladder dysfunction 1
- Weakness, sensory disturbance, and autonomic dysfunction evolve over hours or days, most progressing to maximal clinical severity within 10 days of onset 2
- At maximal clinical severity, half will have a paraparesis, and almost all patients have sensory disturbance and bladder dysfunction 2
- Residual disability is divided equally between severe, moderate and minimal or none 2
Treatment of Transverse Myelitis (TM)
- Acute therapeutic options for TM include corticosteroids, plasma exchange, IV immunoglobulin, and chemotherapeutic agents such as cyclophosphamide 1
- In some instances, combinations of these therapies are used 1
- Early aggressive treatment (usually with EV pulses of methylprednisolone and cyclophosphamide) might improve the prognosis 3
- Cyclophosphamide and steroid therapy were the mainstay of the treatment once the TM had developed 4
- Treatment outcomes were variable, depending mostly on the severity of the neurologic involvement at presentation, timing of the initiation of the therapy and patients adherence with the treatment 4
Etiology and Diagnosis of Transverse Myelitis (TM)
- The causes of transverse myelitis are diverse; etiologies implicated include demyelinating conditions, collagen vascular disease, and parainfectious causes, however, despite extensive diagnostic work-up many cases are considered idiopathic 2
- TM is also a rare complication of Behçet's disease (BD), an autoimmune process 4
- TM associated with BD affected cervical and thoracic levels of the spinal cord 4
- A major association was the history of panuveitis in all four cases of TM associated with BD 4